CD8A and infiltrating bladder urothelial carcinoma: In this regard, clinical outcomes in patients with invasive urothelial carcinoma of the bladder treated with cisplatin-based neoadjuvant chemotherapy were dependent on the ratio of CD8+ to Treg TILs.